Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LIVINGSTON, N.J.--(BUSINESS WIRE)--CoreWeave, Inc. (Nasdaq: CRWV) (“CoreWeave”) announced today the pricing of its private offering of $3.7 billion aggregate principal amount of its 2.875% convertible senior notes due 2033 (the “Notes”). The offering was upsized from the previously announced offering of $3.0 billion aggregate principal amount of Notes. The issuance and sale of the Notes are scheduled to settle on September 22, 2026, subject to customary closing conditions. CoreWeave also grante...

WASHINGTON--(BUSINESS WIRE)--CAVA Group, Inc. (NYSE: CAVA), today announced that its board of directors approved a share repurchase program with authorization to purchase up to $100 million of its outstanding shares of common stock. Repurchases under the program may be made in the open market, in privately negotiated transactions or by other means, including through trading plans intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, with the amount and timing of repurcha...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Solstice Gold Corp (TSXV: SGC) (“Solstice” or the “Company”) today announced its participation in the inaugural Gentile Mining Investor Forum, a full-day investor conference in London on Monday, October 19, 2026, at 116 Pall Mall in Mayfair. The program is presented by strategic junior mining investor Michael Gentile in partnership with Amvest Capital Inc. ("Amvest Capital") and made possible by the generous support of Flagship Sponsors ATB Cormark...

NEW YORK--(BUSINESS WIRE)--ProCap Financial, Inc. (Nasdaq: BRR) (“ProCap Financial” or the “Company”), the first publicly traded agentic finance firm, today announced that it will be included in the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective for trading at the US market open on Monday, September 21, 2026. The index addition comes as ProCap Financial continues to scale Silvia, its AI agent lab exclusively focused on finance. Since its public launch in May 2...

CHICAGO--(BUSINESS WIRE)--Fingerprint, the industry leader in device intelligence, today announced the launch of Bot Directory, a continuously updated, searchable repository of AI tools, bots, and crawlers designed to give customers, partners, and the internet community visibility into automated web traffic. Powered by Fingerprint’s Bot Detection Smart Signal, the public resource helps organizations distinguish human and automated website activities. Bots account for the majority of web traffic...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026...

MILAN, Italy--(BUSINESS WIRE)--Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both n...